Cargando…

IL-6 and IL-8 Serum Levels Predict Tumor Response and Overall Survival after TACE for Primary and Secondary Hepatic Malignancies

While surgical resection represents the standard potentially curative therapy for liver cancer, transarterial chemoembolization (TACE) has evolved as a standard therapy for intermediate-stage hepatocellular carcinoma (HCC) as well as liver metastases. However, it is still not fully understood which...

Descripción completa

Detalles Bibliográficos
Autores principales: Loosen, Sven H., Schulze-Hagen, Maximilian, Leyh, Catherine, Benz, Fabian, Vucur, Mihael, Kuhl, Christiane, Trautwein, Christian, Tacke, Frank, Bruners, Philipp, Roderburg, Christoph, Luedde, Tom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032291/
https://www.ncbi.nlm.nih.gov/pubmed/29899223
http://dx.doi.org/10.3390/ijms19061766
_version_ 1783337479487619072
author Loosen, Sven H.
Schulze-Hagen, Maximilian
Leyh, Catherine
Benz, Fabian
Vucur, Mihael
Kuhl, Christiane
Trautwein, Christian
Tacke, Frank
Bruners, Philipp
Roderburg, Christoph
Luedde, Tom
author_facet Loosen, Sven H.
Schulze-Hagen, Maximilian
Leyh, Catherine
Benz, Fabian
Vucur, Mihael
Kuhl, Christiane
Trautwein, Christian
Tacke, Frank
Bruners, Philipp
Roderburg, Christoph
Luedde, Tom
author_sort Loosen, Sven H.
collection PubMed
description While surgical resection represents the standard potentially curative therapy for liver cancer, transarterial chemoembolization (TACE) has evolved as a standard therapy for intermediate-stage hepatocellular carcinoma (HCC) as well as liver metastases. However, it is still not fully understood which patients particularly benefit from TACE. Cytokines represent a broad category of signaling molecules that might reflect concomitant inflammation as an adverse prognostic factor. Here, we evaluated the role of interleukin (IL)-6, IL-8, and CC-chemokine ligand (CCL)22 as biomarkers in the context of TACE treatment. Cytokine serum levels were analyzed by multiplex immunoassay in 54 patients (HCC: n = 44, liver metastases: n = 10) undergoing TACE as well as 51 healthy controls. Patients with primary and secondary liver cancer showed significantly elevated levels of IL-6 and IL-8 but not CCL22 compared to healthy controls. Interestingly, low pre-interventional levels of IL-6 and IL-8 were predictors for an objective response after TACE in binary logistic regression. In contrast, patients with high pre-interventional IL-6 and IL-8 serum levels not only poorly responded to TACE but had a significantly impaired overall survival. Serum levels of IL-6 and IL-8 represent promising biomarkers for patients undergoing TACE and might help to pre-interventionally identify patients who particularly benefit from TACE regarding objective treatment response and overall survival.
format Online
Article
Text
id pubmed-6032291
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-60322912018-07-13 IL-6 and IL-8 Serum Levels Predict Tumor Response and Overall Survival after TACE for Primary and Secondary Hepatic Malignancies Loosen, Sven H. Schulze-Hagen, Maximilian Leyh, Catherine Benz, Fabian Vucur, Mihael Kuhl, Christiane Trautwein, Christian Tacke, Frank Bruners, Philipp Roderburg, Christoph Luedde, Tom Int J Mol Sci Article While surgical resection represents the standard potentially curative therapy for liver cancer, transarterial chemoembolization (TACE) has evolved as a standard therapy for intermediate-stage hepatocellular carcinoma (HCC) as well as liver metastases. However, it is still not fully understood which patients particularly benefit from TACE. Cytokines represent a broad category of signaling molecules that might reflect concomitant inflammation as an adverse prognostic factor. Here, we evaluated the role of interleukin (IL)-6, IL-8, and CC-chemokine ligand (CCL)22 as biomarkers in the context of TACE treatment. Cytokine serum levels were analyzed by multiplex immunoassay in 54 patients (HCC: n = 44, liver metastases: n = 10) undergoing TACE as well as 51 healthy controls. Patients with primary and secondary liver cancer showed significantly elevated levels of IL-6 and IL-8 but not CCL22 compared to healthy controls. Interestingly, low pre-interventional levels of IL-6 and IL-8 were predictors for an objective response after TACE in binary logistic regression. In contrast, patients with high pre-interventional IL-6 and IL-8 serum levels not only poorly responded to TACE but had a significantly impaired overall survival. Serum levels of IL-6 and IL-8 represent promising biomarkers for patients undergoing TACE and might help to pre-interventionally identify patients who particularly benefit from TACE regarding objective treatment response and overall survival. MDPI 2018-06-14 /pmc/articles/PMC6032291/ /pubmed/29899223 http://dx.doi.org/10.3390/ijms19061766 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Loosen, Sven H.
Schulze-Hagen, Maximilian
Leyh, Catherine
Benz, Fabian
Vucur, Mihael
Kuhl, Christiane
Trautwein, Christian
Tacke, Frank
Bruners, Philipp
Roderburg, Christoph
Luedde, Tom
IL-6 and IL-8 Serum Levels Predict Tumor Response and Overall Survival after TACE for Primary and Secondary Hepatic Malignancies
title IL-6 and IL-8 Serum Levels Predict Tumor Response and Overall Survival after TACE for Primary and Secondary Hepatic Malignancies
title_full IL-6 and IL-8 Serum Levels Predict Tumor Response and Overall Survival after TACE for Primary and Secondary Hepatic Malignancies
title_fullStr IL-6 and IL-8 Serum Levels Predict Tumor Response and Overall Survival after TACE for Primary and Secondary Hepatic Malignancies
title_full_unstemmed IL-6 and IL-8 Serum Levels Predict Tumor Response and Overall Survival after TACE for Primary and Secondary Hepatic Malignancies
title_short IL-6 and IL-8 Serum Levels Predict Tumor Response and Overall Survival after TACE for Primary and Secondary Hepatic Malignancies
title_sort il-6 and il-8 serum levels predict tumor response and overall survival after tace for primary and secondary hepatic malignancies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032291/
https://www.ncbi.nlm.nih.gov/pubmed/29899223
http://dx.doi.org/10.3390/ijms19061766
work_keys_str_mv AT loosensvenh il6andil8serumlevelspredicttumorresponseandoverallsurvivalaftertaceforprimaryandsecondaryhepaticmalignancies
AT schulzehagenmaximilian il6andil8serumlevelspredicttumorresponseandoverallsurvivalaftertaceforprimaryandsecondaryhepaticmalignancies
AT leyhcatherine il6andil8serumlevelspredicttumorresponseandoverallsurvivalaftertaceforprimaryandsecondaryhepaticmalignancies
AT benzfabian il6andil8serumlevelspredicttumorresponseandoverallsurvivalaftertaceforprimaryandsecondaryhepaticmalignancies
AT vucurmihael il6andil8serumlevelspredicttumorresponseandoverallsurvivalaftertaceforprimaryandsecondaryhepaticmalignancies
AT kuhlchristiane il6andil8serumlevelspredicttumorresponseandoverallsurvivalaftertaceforprimaryandsecondaryhepaticmalignancies
AT trautweinchristian il6andil8serumlevelspredicttumorresponseandoverallsurvivalaftertaceforprimaryandsecondaryhepaticmalignancies
AT tackefrank il6andil8serumlevelspredicttumorresponseandoverallsurvivalaftertaceforprimaryandsecondaryhepaticmalignancies
AT brunersphilipp il6andil8serumlevelspredicttumorresponseandoverallsurvivalaftertaceforprimaryandsecondaryhepaticmalignancies
AT roderburgchristoph il6andil8serumlevelspredicttumorresponseandoverallsurvivalaftertaceforprimaryandsecondaryhepaticmalignancies
AT lueddetom il6andil8serumlevelspredicttumorresponseandoverallsurvivalaftertaceforprimaryandsecondaryhepaticmalignancies